CSL (AU:CSL)
ASX:CSL
Want to see AU:CSL full AI Analyst Report?
CSL Stock Chart & Stats
AU$137.13
-AU$0.78(-0.27%)
At close: 4:00 PM EST
AU$137.13
-AU$0.78(-0.27%)
Day’s Range― - ―
52-Week RangeAU$90.00 - AU$275.79
Previous CloseN/A
Volume375.76K
Average Volume (3M)974.43K
Market Cap
AU$51.76B
Enterprise ValueAU$47.57B
Total Cash (Recent Filing)AU$1.15B
Total Debt (Recent Filing)AU$12.58B
Price to Earnings (P/E)25.8
Beta0.69
Next Earnings
Aug 18, 2026EPS Estimate
3.18Next Dividend Ex-DateN/A
Dividend Yield2.58%
Share Statistics
EPS (TTM)2.98
Shares Outstanding478,912,000
10 Day Avg. Volume1,091,561
30 Day Avg. Volume974,433
Financial Highlights & Ratios
PEG Ratio2.89
Price to Book (P/B)5.99
Price to Sales (P/S)7.51
P/FCF Ratio45.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$136.25Price Target Upside-0.64% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.28
Revenue Forecast (FY)AU$15.39B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And MarginsHigh gross and net margins reflect durable pricing power and efficient manufacturing across plasma-derived and specialty therapies. Sustained margins support reinvestment in R&D, fund dividends and buybacks, and provide buffer versus cyclical vaccine seasonality and reimbursement shifts.
Robust Free Cash Flow GenerationStrong FCF growth and efficient conversion of income into cash underpin capital flexibility. This funds ongoing transformation, share buybacks and dividends, and pipeline investment while helping manage moderate leverage and support strategic optionality over the coming years.
New Product And Portfolio MomentumSuccessful launches and growing specialty franchises diversify revenue beyond seasonal vaccines. Rapid uptake of ANDEMBRY and HEMGENIX growth demonstrate commercialization capability, supporting durable revenue streams and lowering reliance on a small set of legacy products.
Bears Say
Ig Portfolio Reimbursement HeadwindsPolicy-driven reimbursement changes in the U.S. and contract dynamics hit core immunoglobulin revenues. Because Ig products are a structural revenue pillar, sustained payer reforms or adverse contracting could depress top-line and margins and require strategic pricing or mix shifts to restore growth.
China Albumin Policy ExposureSignificant exposure to China policy and cost-control enforcement creates durable demand and pricing risk for albumin. Given China’s scale in the portfolio, prolonged controls can erode volumes, utilization and margins, complicating capacity planning and multi-year revenue forecasts.
Iron Franchise Competition And LOE RiskGeneric entrants and imminent loss of exclusivity for key iron therapies are structural threats to revenue and cash flow. Without pipeline replacements or commercial offsets, these product-level declines will pressure growth and require sustained R&D, pricing or M&A responses to preserve long-term margins.
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$90.00 and its highest was AU$275.79 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is AU$51.76B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Aug 18, 2026 which is in 59 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Feb 10, 2026. The company reported AU$5.75 earnings per share for the quarter, missing the consensus estimate of AU$5.907 by -AU$0.157.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Overvalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$1.81 which represents an annual dividend yield of 2.58%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 3.18.
How many shares outstanding does CSL have?
CSL has 478,912,000 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$5.75 in its last earnings report, missing expectations of AU$5.907. Following the earnings report the stock price went down -4.638%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$136.25 (-0.64% Downside)
AU$136.25 (-0.64% Downside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 81%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$457.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 85%
Bearish news 15%
Bearish news 15%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL Company Deck
CSL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: operational strengths (strong cash generation, share buyback expansion, cost-savings progress, solid Vifor performance, successful new product launches and Seqirus commercial gains) are offset by meaningful near-term pressures (H1 revenue decline, major non-cash impairments and one-off restructuring costs, policy-driven weakness in albumin and Ig headwinds, iron generics and KCENTRA competitive pricing). Management emphasizes these impairments are largely non‑cash, that the transformation is delivering tangible savings, and they have maintained full-year guidance while laying out remediation steps for weaker areas. The tone is cautiously constructive but with material near-term risks that require execution in H2 to validate the outlook.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$136.25
▼(-0.64% Downside)
Technical Analysis
Opthea
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---